CuraGen Corporation (Nasdaq: CRGN) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients with advanced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE